• Earlier this month, LeMaitre Vascular reported quarterly revenues of US$66.55 million, an 11.2% year-on-year increase, alongside an earnings beat versus analyst expectations, but paired this with comparatively weaker full-year guidance than its peer group.
• Management is also actively engaging investors through recent and upcoming appearances at major healthcare conferences hosted by Bank of America, Jefferies, and Goldman Sachs, signaling a focus on explaining the company’s outlook and capital allocation plans to the market.
• Next, we’ll examine how robust quarterly results but softer full-year guidance could reshape LeMaitre Vascular’s investment narrative and risk profile.

Find 51 companies with promising cash flow potential yet trading below their fair value.

LeMaitre Vascular Investment Narrative Recap

To own LeMaitre Vascular, you need to believe its niche focus in vascular surgery, expanding international footprint, and aging patient base can support steady growth despite its relatively concentrated product portfolio and pricing sensitivity. The latest quarter’s revenue beat and EPS outperformance, followed by a share price pullback after softer guidance versus peers, does not materially change the near term catalyst of executing on international expansion, but it does sharpen the risk that expectations for growth and pricing may prove too optimistic.

The most relevant recent development is LeMaitre’s Q1 2026 update, where it delivered US$66.55 million in sales, up 11.2% year on year, while also raising full year 2026 guidance to US$277 million to US$283 million in sales and US$2.93 to US$3.08 in EPS. Set against a 10% share price drop after results, this guidance and the company’s ongoing participation in major healthcare conferences frame the key catalyst of sustaining growth without relying too heavily on temporary stocking orders or aggressive price increases.

Yet beneath the strong recent numbers, investors should be aware of how much of LeMaitre’s growth is tied to price hikes and temporary stocking demand...

LeMaitre Vascular's narrative projects $330.8 million revenue and $80.9 million earnings by 2029. This requires 9.8% yearly revenue growth and about a $23.2 million earnings increase from $57.7 million today.

Uncover how LeMaitre Vascular's forecasts yield a $111.22 fair value, a 10% upside to its current price.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community span roughly US$66.62 to over US$5,300, showing just how widely individual views on LeMaitre can differ. Against that backdrop, the recent mix of strong quarterly results but relatively weaker guidance than peers highlights how assumptions about sustainable unit growth and pricing power can meaningfully shape expectations for the company’s future performance.

Explore 4 other fair value estimates on LeMaitre Vascular - why the stock might be worth 34% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your LeMaitre Vascular research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free LeMaitre Vascular research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate LeMaitre Vascular's overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.